Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myr-K(DOTA)-c(RGDfK)
- Development stage
- Preclinical
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Myr-K(DOTA)-c(RGDfK) is a myristic acid-conjugated cyclic RGD peptide (c(RGDfK)) linked to a DOTA chelator, developed by the National Cancer Center of Japan, Osaka Medical and Pharmaceutical University, and Linqmed. It is designed for integrin-targeted peptide receptor radionuclide therapy (PRRT) and molecular imaging of cancers, particularly pancreatic cancer. The cyclic RGDfK peptide moiety selectively targets integrins αvβ3 and αvβ6, which are highly expressed on pancreatic cancer cells and tumor-associated vasculature. The conjugation of myristic acid (a C14 fatty acid) serves as a serum albumin binder, which significantly enhances blood retention and tumor accumulation by slowing renal clearance. The DOTA chelator allows for radiolabeling with various radionuclides, such as indium-111 (111In) for diagnostic imaging, or actinium-225 (225Ac) and lutetium-177 (177Lu) for targeted alpha/beta radionuclide therapy.
- Other names
- Myr-K(111In-DOTA)-c(RGDfK)Myr-K(177Lu-DOTA)-c(RGDfK)Myr-K(225Ac-DOTA)-c(RGDfK)myristic acid-conjugated RGD peptide
02
Targets
αVβ3 (Integrin αVβ3)αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on Myr-K(DOTA)-c(RGDfK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myr-K(DOTA)-c(RGDfK).